Merck Nixes study on prostate cancer where Keytruda therapy disappoints

Published Date: 02 Mar 2023

Merck & Co has halted late-stage trials of the combination with cancer drug Keytruda because preliminary data showed it was unlikely to achieve its primary goal.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Global inequalities found in cancer research funding

2.

Breast cancer surgery: Study finds overnight hospital stay not important for older patients

3.

Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.

4.

AI System Beats Radiologists in Detecting Clinically Significant Prostate Cancer

5.

Fighting for others: How guilt and obligation drive desire for more intensive treatments in end-of-life cancer care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot